why choose us

First received: February 10, 2023

Clinical Trial: Expanded Access to Ziftomenib

Condition: Acute Lymphoblastic Leukemia, With Appropriate Mutations
Acute Myeloid Leukemia, With NPM1 Muta

Study Type: Expanded Access


Official Title: Expanded Access to Ziftomenib

Brief Summary: Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL), with appropriate mutations, or Acute Myeloid Leukemia (AML), with NPM1 mutations.To request access, use Responsible Party contact information provided in this record.Expanded access for ziftomenib is only available in the United States

Read more